Living Cell Technologies Limited (ASX:LCT)(OTCQX:LVCLY), a global company pioneering the development of a cell implant to treat diabetes, today provided a penultimate update regarding the three-year follow up of its Phase I/IIa clinical trial in Russia of its DIABECELL® treatment in insulin-dependent diabetics. The data analysis has confirmed that the trial has successfully met its end points of demonstrating safety and tolerability. In addition, the groundbreaking treatment has shown proof of principle of efficacy in humans with insulin-dependent (Type 1) diabetes. These results have been accepted for oral presentation at the scientific meeting of the American Diabetes Association in June. These positive data, taken together with positive progress in LCT's Phase II trial in New Zealand, provide encouragement to progress DIABECELL® further towards commercialisation.
“We are pleased with the progress we are making with DIABECELL® in our trials in Russia and New Zealand. Our Phase II trial in New Zealand will help us to determine the optimum dosing regimen. We are thus pleased to be making positive progress towards commercialisation.”
Prof. Bob Elliott, LCT Medical Director said, "We are pleased that our treatment has shown so far to be safe and well tolerated. We are encouraged that we have demonstrated that DIABECELL® may be safely administered up to three times and that we have seen evidence of continuing efficacy exemplified by the patients clearly showing reduced HbA1c levels as well as the daily dose of insulin injections, with better control over their blood glucose levels. Patients volunteered that they sensed greater well being."
DIABECELL® is LCT's treatment designed to normalise the lives of people with insulin-dependent diabetes. DIABECELL® comprises encapsulated porcine insulin-producing cells (islets) that are implanted into the abdomen of patients using a simple laparoscopic procedure, and work by self-regulating and efficiently secreting insulin in the patient's body. LCT's breakthrough proprietary encapsulation technology means that patients receiving DIABECELL® treatment do not require immunosuppressant drugs after implantation.
Prof. Boris Draznin, Director of the Adult Diabetes Program at University of Colorado Denver, School of Medicine, who has long followed islet transplantation, said, "This is the first time that anyone with long term insulin-dependent diabetes has come off insulin injections following islet cell implants without using immunosuppressant drugs."
The trial, which commenced in June 2007, is reported for the eight patients. The patients, between 21 and 68 years of age with insulin-dependent diabetes have received between one and three implants of DIABECELL® with only minor adverse events. Blood samples taken from patients over the past 34 months have tested negative for any pig-to-human transmission of diseases. Six of the eight patients have shown improvements in blood glucose control as reflected by reduction in glycated haemoglobin (HbA1c %) levels and reduction of the required daily dose of insulin injections. Two patients discontinued insulin injections entirely; the longest period was for a span of 14 weeks. The trial was conducted in the Sklifosovsky Institute Moscow.
All trial patients will continue to be monitored to establish the duration of clinical benefit and safety. LCT is investigating the possibilities of conducting additional trials in other jurisdictions. LCT also recently reported that DIABECELL® has also progressed to the next stage if its Phase II studies in New Zealand having received approval from the New Zealand Data Safety and Monitoring Board in late March to advance to implants at higher doses.
Dr Paul Tan, Chief Executive Officer for LCT, said, "We are pleased with the progress we are making with DIABECELL® in our trials in Russia and New Zealand. Our Phase II trial in New Zealand will help us to determine the optimum dosing regimen. We are thus pleased to be making positive progress towards commercialisation."
Insulin resistance linked to 31 diseases and higher early death risk in women